Identification of a candidate drug for the prevention of cisplatin-induced nephrotoxicity by a database analysis-basic research-clinical study
-
- Ikeda Yasumasa
- Dept. Pharmacol. Tokushima Univ.
-
- Hamano Hirofumi
- Dept. Pharm. Tokushima Univ. Hosp.
-
- Goda Mitsuhiro
- Dept. Pharm. Tokushima Univ. Hosp.
-
- Fukushima Keijo
- Dept. Pharmacol. Life Sci.
-
- Kishi Seiji
- Dept. General Med. Kawasaki Med. Hosp.
-
- Chuma Masayuki
- Clin. Trial Ctr. Tokushima Univ. Hosp.
-
- Zamami Yoshito
- Dept. Clin. Pharmacol. Tokushima Univ.
-
- Miyamoto Licht
- Dept. Med. Pharmacol. Tokushima Univ.
-
- Ishizawa Keisuke
- Dept. Clin. Pharmacol. Tokushima Univ.
-
- Fujino Hiromichi
- Dept. Pharmacol. Life Sci.
-
- Aihara Ken-ichi
- Dept. Comm. Med. and Med. Sci.
-
- Tsuchiya Koichiro
- Dept. Med. Pharmacol. Tokushima Univ.
-
- Tamaki Toshiaki
- Anan Med. Ctr.
Bibliographic Information
- Other Title
-
- シスプラチン起因性腎障害の予防薬の同定
Description
<p>Background: Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. Unfortunately, it causes nephrotoxicity as a critical side effect, limiting its use, given that no preventive drug against cisplatin-induced nephrotoxicity (CIN) is currently available. In the present study, we searched and identified candidate drugs for preventing CIN</p><p>Methods: We used a database of medical big data for the screening of candidate drugs for the prevention of CIN. Based on the results of the analysis of medical big data, we evaluated the actual efficacy of DPH via in vitro and in vivo experiments in culture cells and a mouse model.</p><p>Results: We identified that a previously developed drug, diphenhydramine (DPH), may provide a novel treatment for CIN by the analysis of medical big data. DPH inhibited cisplatin-induced cell death in renal proximal tubular cells. Mice administered cisplatin developed kidney injury with renal dysfunction, augmented oxidative stress, increased apoptosis, and elevated inflammatory cytokines; however, most of these symptoms were suppressed by treatment with DPH. Additionally, the renal concentration of cisplatin was attenuated in DPH-treated mice. Importantly, DPH did not i interfere with its anti-tumor effect in any of the in vitro or in vivo experiments. Moreover, a retrospective clinical study showed that patients with malignant cancer who had used DPH before cisplatin treatment exhibited less acute kidney injury. </p><p>Conclusion: DPH may be a preventive medicine against CIN.</p>
Journal
-
- Proceedings for Annual Meeting of The Japanese Pharmacological Society
-
Proceedings for Annual Meeting of The Japanese Pharmacological Society 94 (0), 2-O-D3-1-, 2021
Japanese Pharmacological Society
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390850391141166208
-
- NII Article ID
- 130008001359
-
- ISSN
- 24354953
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- Abstract License Flag
- Disallowed